Literature DB >> 25698065

Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.

Phillip M Pierorazio1, Michael H Johnson2, Mark W Ball2, Michael A Gorin2, Bruce J Trock2, Peter Chang3, Andrew A Wagner3, James M McKiernan4, Mohamad E Allaf2.   

Abstract

BACKGROUND: A growing body of retrospective literature is emerging regarding active surveillance (AS) for patients with small renal masses (SRMs). There are limited prospective data evaluating the effectiveness of AS compared to primary intervention (PI).
OBJECTIVE: To determine the characteristics and clinical outcomes of patients who chose AS for management of their SRM. DESIGN, SETTING, AND PARTICIPANTS: From 2009 to 2014, the multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry prospectively enrolled 497 patients with solid renal masses ≤4.0cm who chose PI or AS. INTERVENTION: AS versus PI. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The registry was designed and powered as a noninferiority study based on historic recurrence rates for PI. Analyses were performed in an intention-to-treat manner. Primary outcomes were overall survival (OS) and cancer-specific survival (CSS). RESULTS AND LIMITATIONS: Of the 497 patients enrolled, 274 (55%) chose PI and 223 (45%) chose AS, of whom 21 (9%) crossed over to delayed intervention. AS patients were older, had worse Eastern Cooperative Oncology Group scores, total comorbidities, and cardiovascular comorbidities, had smaller tumors, and more often had multiple and bilateral lesions. OS for PI and AS was 98% and 96% at 2 yr, and 92% and 75% at 5 yr, respectively (log rank, p=0.06). At 5 yr, CSS was 99% and 100% for PI and AS, respectively (p=0.3). AS was not predictive of OS or CSS in regression modeling with relatively short follow-up.
CONCLUSIONS: In a well-selected cohort with up to 5 yr of prospective follow-up, AS was not inferior to PI. PATIENT
SUMMARY: The current report is among the first prospective analyses of patients electing for active surveillance of a small renal mass. Discussion of active surveillance should become part of the standard discussion for management of small renal masses.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Kidney neoplasm; Outcomes; Renal cell carcinoma; Treatment

Mesh:

Year:  2015        PMID: 25698065     DOI: 10.1016/j.eururo.2015.02.001

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  74 in total

Review 1.  Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry.

Authors:  Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

Review 2.  Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions.

Authors:  Anand Swaminath; William Chu
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

3.  Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size.

Authors:  Brian R Winters; John L Gore; Sarah K Holt; Jonathan D Harper; Daniel W Lin; Jonathan L Wright
Journal:  Urol Oncol       Date:  2015-08-28       Impact factor: 3.498

4.  Kidney cancer: Surveillance not inferior in SRM.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2015-03-03       Impact factor: 14.432

5.  Predicting aggressive behavior in small renal tumors prior to treatment.

Authors:  Daniel D Shapiro; E Jason Abel
Journal:  Ann Transl Med       Date:  2018-12

6.  Kidney cancer: Emerging guidelines for managing small renal masses.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Nat Rev Urol       Date:  2017-03-14       Impact factor: 14.432

Review 7.  Treatment approaches to small renal masses in patients of advanced age (≥75 years).

Authors:  Muhammet Fuat Özcan; Serkan Altınova; Ali Atan
Journal:  Turk J Urol       Date:  2018-07

Review 8.  Imaging Protocols for Active Surveillance in Renal Cell Carcinoma.

Authors:  Christine W Liaw; Jared S Winoker; Reza Mehrazin
Journal:  Curr Urol Rep       Date:  2018-08-13       Impact factor: 3.092

Review 9.  Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease.

Authors:  Jad Chahoud; Melissa McGettigan; Nainesh Parikh; Ronald S Boris; Othon Iliopoulos; W Kimryn Rathmell; Anthony B Daniels; Eric Jonasch; Philippe E Spiess
Journal:  World J Urol       Date:  2020-09-16       Impact factor: 4.226

Review 10.  Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of 99mTc-MIBI SPECT/CT.

Authors:  Andrew M Reynolds; Kristin Kelly Porter
Journal:  Curr Urol Rep       Date:  2017-09-12       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.